title: The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.
abstract: An association exists between respiratory viruses and bacterial infections. Prevention or treatment of the preceding viral infection is a logical goal for reducing this important cause of morbidity and mortality. The ability of the novel, selective parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 to prevent the synergism between a paramyxovirus and Streptococcus pneumoniae was examined in this study. A model of secondary bacterial pneumonia after infection with a recombinant Sendai virus whose hemagglutinin-neuraminidase gene was replaced with that of human parainfluenza virus type 1 [rSV(hHN)] was established in mice. Challenge of mice with a sublethal dose of S. pneumoniae 7 days after a sublethal infection with rSV(hHN) (synergistic group) caused 100% mortality. Bacterial infection preceding viral infection had no effect on survival. The mean bacterial titers in the synergistic group were significantly higher than in mice infected with bacteria only. The virus titers were similar in mice infected with rSV(hHN) alone and in dually infected mice. Intranasal administration of BCX 2798 at 10 mg/kg per day to the synergistic group of mice starting 4 h before virus infection protected 80% of animals from death. This effect was accompanied by a significant reduction in lung viral and bacterial titers. Treatment of mice 24 h after the rSV(hHN) infection showed no protection against synergistic lethality. Together, our results indicate that parainfluenza viruses can prime for secondary bacterial infections. Prophylaxis of parainfluenza virus infections with antivirals might be an effective strategy for prevention of secondary bacterial complications in humans.
authors.affiliation: Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105-2794, USA.
authors.forename: Irina V
authors.initials: IV
authors.lastname: Alymova
authors.forename: Allen
authors.initials: A
authors.lastname: Portner
authors.forename: Toru
authors.initials: T
authors.lastname: Takimoto
authors.forename: Kelli L
authors.initials: KL
authors.lastname: Boyd
authors.forename: Y Sudhakara
authors.initials: YS
authors.lastname: Babu
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: McCullers
mesh_terms: D000818:Animals; D001386:Azides / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D015707:HN Protein / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D006603:Hexuronic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008168:Lung / Q000382:microbiology / Q000821:virology; D051379:Mice; D010222:Parainfluenza Virus 1, Human / Q000235:genetics / Q000378:metabolism / Q000472:pathogenicity; D011018:Pneumonia, Pneumococcal / Q000401:mortality* / Q000517:prevention & control*; D010253:Respirovirus Infections / Q000150:complications* / Q000188:drug therapy / Q000401:mortality / Q000821:virology; D029082:Sendai virus / Q000235:genetics / Q000378:metabolism; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000472:pathogenicity
chemical_list: C486444:4-zido-5-isobutyrylamino-2,3-didehydro-2,3,4,5-tetradeoxyglycerogalacto-2-nonulopyranosic acid; D001386:Azides; D015707:HN Protein; D006603:Hexuronic Acids